Denileukin diftitox and vision loss.
Ruddle
J B
JB
Royal Victorian Eye and Ear Hospital, East Melbourne, Australia. jonathan.ruddle@eyeandear.org.au
Prince
H Miles
HM
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004167:Diphtheria Toxin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000175:diagnosis*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy*; D014786:Vision Disorders / Q000139:chemically induced*
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox